Evidence map›Paper›PMID 39349170›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2025

Gene expression-based molecular scoring of pancreas transplant rejection for a quantitative assessment of rejection severity and resistance to treatment.

Audrey E Brown, Yvonne M Kelly, Arya Zarinsefat, Raphael P H Meier, Giulia Worner, Mehdi Tavakol, Minnie M Sarwal, Zoltan G Laszik, Peter G Stock, Tara K Sigdel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Audrey E BrownDepartment of Surgery, University of California, San Francisco, California, USA.
Yvonne M KellyDepartment of Surgery, University of California, San Francisco, California, USA; Department of Surgery, Columbia University, New York, New York, USA.
Arya ZarinsefatDepartment of Surgery, University of California, San Francisco, California, USA.
Raphael P H MeierDepartment of Surgery, University of California, San Francisco, California, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Giulia WornerDepartment of Surgery, University of California, San Francisco, California, USA.
Mehdi TavakolDepartment of Surgery, University of California, San Francisco, California, USA.
Minnie M SarwalDepartment of Surgery, University of California, San Francisco, California, USA.
Zoltan G LaszikDepartment of Surgery, University of California, San Francisco, California, USA.
Peter G StockDepartment of Surgery, University of California, San Francisco, California, USA. Electronic address: peter.stock@ucsf.edu.
Tara K SigdelDepartment of Surgery, University of California, San Francisco, California, USA. Electronic address: tara.sigdel@ucsf.edu.

Funding

Filling a Void of Research (FAVOR) Training for Transplant SurgeonsT32AI125222 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER G STOCK, Minnie M Sarwal · 2016 to 2026
$3.4M
NIAID NIH HHS T32 AI125222
6 · The paper itself

Abstract

Pancreas transplantation improves glycemic control and mortality in patients with diabetes but requires aggressive immunosuppression to control the alloimmune and autoimmune response. Recent developments in "omics" methods have provided gene transcript-based biomarkers for organ transplant rejection. The tissue Common Response Module (tCRM) score is developed to identify the severity of rejection in kidney, heart, liver, and lung transplants. Still, it has not yet been validated in pancreas transplants (PT). We evaluated the tCRM score's relevance in PT and additional markers of acute cellular rejection (ACR) for PT. An analysis of 51 pancreas biopsies with ACR identified 37 genes and 56 genes significantly upregulated in the case of grade 3 and grade 2 ACR, respectively (P < .05). Significant differences were seen with higher grades of rejection among several transcripts. Of the 22 genes differentially expressed in grade 3 ACR, 18 were also differentially expressed in grade 2 ACR. The rejection signal was attributable to activated leukocytes' infiltration. Significantly higher tCRM scores were found in grade 3 ACR (P = .007) and grade 2 ACR (P = .004), compared to normal samples. The tCRM score was able to distinguish treatment-resistant cases from those successfully treated for rejection.

Indexed as

BiomarkersGene Expression ProfilingGraft RejectionPancreas TransplantationAdultFemaleFollow-Up StudiesGraft SurvivalHumansMaleMiddle AgedPrognosisSeverity of Illness IndexBiomarkersacute cellular rejectiondifferential gene expressionpancreas transplanttissue Common Response Module score

Identifiers

PMID39349170
PMCPMC11878653

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.